IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received an average recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $187.33.

Several equities research analysts have issued reports on IDXX shares. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. BidaskClub lowered IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Aegis reaffirmed a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target for the company in a research note on Tuesday, October 24th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, October 24th.

In other news, Chairman Jonathan W. Ayers sold 54,000 shares of the business’s stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total value of $8,171,280.00. Following the completion of the sale, the chairman now owns 1,064,573 shares of the company’s stock, valued at approximately $161,091,186.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $165.15, for a total value of $2,972,700.00. Following the completion of the sale, the chief executive officer now directly owns 1,077,112 shares of the company’s stock, valued at approximately $177,885,046.80. The disclosure for this sale can be found here. In the last three months, insiders sold 130,160 shares of company stock valued at $20,019,685. 2.77% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IDXX. Koch Industries Inc. lifted its stake in shares of IDEXX Laboratories by 44,533.1% in the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after acquiring an additional 1,396,113 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of IDEXX Laboratories by 486.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock valued at $182,711,000 after acquiring an additional 938,888 shares during the last quarter. BlackRock Inc. lifted its stake in shares of IDEXX Laboratories by 10.5% in the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares during the last quarter. Atlantic Trust Group LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $65,381,000. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of IDEXX Laboratories by 42.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after acquiring an additional 392,790 shares during the last quarter. 86.66% of the stock is owned by institutional investors.

IDEXX Laboratories (IDXX) traded up $3.57 during trading on Tuesday, reaching $176.81. The company had a trading volume of 242,755 shares, compared to its average volume of 482,989. IDEXX Laboratories has a twelve month low of $116.54 and a twelve month high of $173.82. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. The stock has a market capitalization of $15,370.00, a PE ratio of 57.41, a price-to-earnings-growth ratio of 2.34 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. The company’s revenue was up 9.7% compared to the same quarter last year. equities research analysts predict that IDEXX Laboratories will post 3.24 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “IDEXX Laboratories, Inc. (IDXX) Given Consensus Recommendation of “Hold” by Analysts” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/idexx-laboratories-inc-idxx-given-consensus-recommendation-of-hold-by-analysts/1809361.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.